These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 11433750)

  • 1. [Screening methods in the detection of bladder cancer: comparison of nuclear matrix protein-22, bladder tumor antigen and cytological examinations].
    Fukui Y; Samma S; Fujimoto K; Akiyama T; Yamaguchi A; Hirayama A
    Hinyokika Kiyo; 2001 May; 47(5):311-4. PubMed ID: 11433750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of nuclear matrix protein 22 and bladder tumor antigen in urine of patients with bladder cancer.
    Abbate I; D'Introno A; Cardo G; Marano A; Addabbo L; Musci MD; Pagliarulo A; Correale M; Quaranta M
    Anticancer Res; 1998; 18(5B):3803-5. PubMed ID: 9854500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparative study of BTA stat test, NMP-22, and cytology in the diagnosis of bladder cancer].
    Gutiérrez Baños JL; Rebollo Rodrigo MH; Antolín Juarez F; Martín García B; Hernández Rodríguez R; Portillo Martín JA; Correas Gómez MA; del Valle Schaan JI; Roca Edreira A; de Diego Rodríguez E; Radó Velázquez MA
    Arch Esp Urol; 2000; 53(1):21-7. PubMed ID: 10730421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparisons of voided urine cytology, nuclear matrix protein-22 and bladder tumor associated antigen tests for bladder cancer of geriatric male patients in Taiwan, China.
    Tsui KH; Chen SM; Wang TM; Juang HH; Chen CL; Sun GH; Chang PL
    Asian J Androl; 2007 Sep; 9(5):711-5. PubMed ID: 17712491
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
    Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
    J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Quantification of bladder tumor antigen (BTA trak) and its correlation with bladder cancer grade and stage].
    Rodríguez Martínez JJ; Escaf Barmadah S; Allende MT; Raigoso P; Martín Benito JL; Pérez García FJ; Fernández Gómez JM
    Arch Esp Urol; 2000; 53(1):1-6. PubMed ID: 10730418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of urine-based markers for detection and monitoring of bladder cancer.
    Pirtskalaishvili G; Getzenberg RH; Konety BR
    Tech Urol; 1999 Dec; 5(4):179-84. PubMed ID: 10591254
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence.
    Boman H; Hedelin H; Holmäng S
    J Urol; 2002 Jan; 167(1):80-3. PubMed ID: 11743280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of urinary nuclear matrix protein 22 as a marker for bladder cancer].
    Kurokawa S; Morita T; Muraishi O; Tokue A
    Hinyokika Kiyo; 2001 Apr; 47(4):247-50. PubMed ID: 11411098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Urinary tumor marker for urothelial cancer].
    Ohtani M; Iwasaki A; Shiraiwa H
    Gan To Kagaku Ryoho; 2001 Nov; 28(12):1933-7. PubMed ID: 11729491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
    Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
    J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
    Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
    Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Bard BTA test with voided urine and bladder wash cytology in the diagnosis and management of cancer of the bladder.
    Leyh H; Hall R; Mazeman E; Blumenstein BA
    Urology; 1997 Jul; 50(1):49-53. PubMed ID: 9218018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of nuclear matrix protein 22 combined with bladder tumor antigen stat test in surveillance of recurring bladder cancer.
    Xu K; Tam PC; Hou S; Wang X; Bai W
    Chin Med J (Engl); 2002 Nov; 115(11):1736-8. PubMed ID: 12609098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of the bladder tumor marker "Tu-MARK-BTA"].
    Yogi S; Ikeuchi T; Yoshikawa H; Hamashima T; Sasaki H; Morikawa F; Onodera Y; Matsumoto K; Kai Y
    Hinyokika Kiyo; 1991 Apr; 37(4):335-9. PubMed ID: 1891992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
    Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
    Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Determination of NMP-22 as recurrence marker in bladder cancer. Preliminary study].
    Pérez García FJ; Escaf Barmadah S; Fernández Gómez JM; Rodríguez Martínez JJ; Martín Benito JL
    Arch Esp Urol; 2000 May; 53(4):305-12. PubMed ID: 10900760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.